Skip to main content

Table 1 Clinical characteristic of the patients with COVID-19 at admission

From: Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients

ItemOverallMild groupSevere groupP-value
Male [n (%)]56/105 (53.3)38/79 (48.1)18/26 (69.2)0.073
Age (year, IQR)45.0 [33.5, 59.5]
(n = 105)
41.0 [33.0, 56.0]
(n = 79)
59.0 [48.5, 69.8]
(n = 26)
< 0.001
Disease duration (d, IQR)5.0 [3.0, 8.0]
(n = 105)
4.0 [2.0, 7.0]
(n = 79)
7.0 [5.0, 10.25]
(n = 26)
0.005
Hospital stay (d, IQR)22.0 [17.0, 31.5]
(n = 105)
20.0 [16.0, 28.0]
(n = 79)
31.5 [22.5, 35.5]
(n = 26)
0.001
Fatty liver by ultrasound [n (%)]37/89 (41.6)26/65 (40.0)11/24 (45.8)0.636
Hypertension [n (%)]15/105 (14.3)9/79 (11.4)6/26 (23.1)0.190
Diabetes [n (%)]6/105 (5.7)3/79 (3.8)3/26 (11.5)0.160
HBsAg (+) [n (%)]0/22 (0)0/14 (0)0/8 (0)
Anti-HCV (+) [n (%)]1/22 (0)0/14 (0)1/8 (12.5)0.364
Heavy alcohol use [n (%)]1/105 (1.0)1/79 (1.3)0/26 (0)1.000
ALT (U/L, IQR)23.5 [14.0, 36.0]
(n = 105)
22.0 [14.0, 34.5]
(n = 79)
27.8 [18.8, 38.0]
(n = 26)
0.088
  < 1 × ULN [n (%)]88 (83.8)67 (84.8)21 (80.8)0.482
1–2 × ULN [n (%)]13 (12.4)10 (12.7)3 (11.5)
≥2 × ULN [n (%)]4 (3.8)2 (2.5)2 (7.7)
AST (U/L, IQR)24.2 [19.7, 34.8]
(n = 50)
22.0 [18.4, 31.7]
(n = 39)
46.3 [25.5, 54.3] (n = 11)< 0.001
< 1 × ULN [n (%)]41 (82.0)37 (94.9)4 (36.4)< 0.001
1–2 × ULN [n (%)]8 (16.0)2 (5.1)6 (54.5)
≥2 × ULN [n (%)]1 (2.0)0 (0)1(9.1)
TBil (umol/L, IQR)10.2 [7.4, 12.9]
(n = 50)
10.0 [7.1, 12.9]
(n = 39)
10.6 [8.3, 12.9] (n = 11)0.535
< 1 × ULN [n (%)]48 (96.0)38 (97.4)10 (90.9)0.395
1–2 × ULN [n (%)]2 (4.0)1 (2.6)1 (9.1)
≥2 × ULN [n (%)]0 (0)0 (0)0 (0)
CHE (U/L, IQR)7490 [6801, 9527] (n = 50)6517 [6843, 9682] (n = 39)6972 [4893, 8459] (n = 11)0.137
ALB (g/L, IQR)41.6 [37.9, 44.7]
(n = 49)
42.0 [38.7, 45.5]
(n = 39)
37.2 [34.2, 41.8] (n = 10)0.012
  1. IQR interquartile range, ALT alanine aminotransferase, AST aspartate aminotransferase, TBil total bilirubin. ALB albumin, CHE cholinesterase